ReAlta Life Sciences Revenue and Competitors
Estimated Revenue & Valuation
- ReAlta Life Sciences's estimated annual revenue is currently $3.1M per year.
- ReAlta Life Sciences's estimated revenue per employee is $155,000
Employee Data
- ReAlta Life Sciences has 20 Employees.
- ReAlta Life Sciences grew their employee count by -26% last year.
ReAlta Life Sciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Senior Director, Business Operations and Hypoxic Ischemic Encephalopathy Program Leader | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | Chief Scientific Officer | Reveal Email/Phone |
ReAlta Life Sciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.4M | 9 | -10% | N/A | N/A |
#2 | $4.3M | 28 | 4% | N/A | N/A |
#3 | $1.1M | 7 | 0% | N/A | N/A |
#4 | $3.5M | 45 | -52% | $56.5M | N/A |
#5 | $0.3M | 2 | 0% | N/A | N/A |
#6 | $4.5M | 29 | 21% | N/A | N/A |
#7 | $1.9M | 12 | 9% | N/A | N/A |
#8 | $7M | 45 | 5% | N/A | N/A |
#9 | $6.7M | 43 | 5% | N/A | N/A |
#10 | $2M | 13 | -13% | N/A | N/A |
What Is ReAlta Life Sciences?
ReAlta Life Sciences, Inc. is a clinical stage biotech company dedicated to harnessing the power of the immune system through its EPICC technology platform, comprised of a family of over 160 engineered peptides, to address life-threatening medical needs. The peptide family leverages one billion years of evolution that has enabled the human astrovirus to inhibit components of the innate immune system. This novel class of therapeutics exploits the virus' dual targeting approach and enables the rebalancing of complement and inflammatory processes in the body. The company's pipeline is led by RLS-0071, which has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates, and is also being developed as a treatment for acute lung injury secondary to COVID-19. The company launched in 2018, and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com.
keywords:N/A
N/A
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
-26%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ReAlta Life Sciences News
ReAlta Life Sciences' RLS-0071 Demonstrates Excellent Safety Profile and Confirmed Target Engagement in First-in-Human Phase 1 Clinical Trial.
--(BUSINESS WIRE)--ReAlta Life Sciences (ReAlta), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune...
ReAlta Life Sciences has obtained clearance for its Investigational New Drug (IND) application from the US Food and Drug Administration...
Other Companies in Norfolk
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.1M | 20 | 0% | N/A |
#2 | $1.4M | 20 | -9% | N/A |
#3 | $4.3M | 21 | -51% | N/A |
#4 | $4.3M | 21 | -12% | N/A |
#5 | $4.4M | 21 | -22% | N/A |